又添13感染群 10个涉职场 seehua.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seehua.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
SAN DIEGO, Jan. 8, 2021 /PRNewswire/ Denovo Biopharma LLC, a pioneer in applying precision medicine to development of innovative therapies, today announced dosing of the first patient in its biomarker guided Phase 3 clinical study evaluating the DB102 (enzastaurin) in combination with temozolomide and radiation as first line therapy to treat newly-diagnosed glioblastoma multiforme (GBM). This randomized, double-blind, placebo-controlled global study is to enroll more than 300 patients and the primary outcome measure is overall survival in patients with Denovo Genomic Marker 1 (DGM1). This GBM study has received Phase 3 permission from regulatory agencies from US, Canada, and China, and also gained FDA s Fast Track designation last year.